CODEXIS, INC. business relationships
Companies named in CODEXIS, INC.’s 10-K filed 2026-03-11, and public companies whose annual reports name CODEXIS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 33 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 2 / 100
Named in CODEXIS, INC.’s annual report 18
“...es include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at developing processes...” SEC filing
“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing
“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing
“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing
“Revenue relating to the functional licenses provided to Takeda was recognized at a point in time when the control of the license transferred to the customer.” SEC filing
“The increase was primarily due to $34.0 million higher revenue from our licensing agreements with Merck entered into during the second and fourth quarters of 2025, and $3.3 million higher revenue from existing and legacy collaboration agreements.” SEC filing
“In May 2019, we entered into a Platform Technology Transfer and License Agreement (the "Novartis CodeEvolver” SEC filing
“Pursuant to the agreement, 90 % of the fee ($ 23.3 million) was creditable toward (i) qualifying CDX-616 orders shipped through December 31, 2023, and (ii) fees associated with new development or licensing agreements with Pfizer entered into before April 4, 2023.” SEC filing
“In December 2019, we entered into a license agreement with Roche to provide Roche with our evolved T4 DNA ligase high-performance molecular diagnostic enzyme.” SEC filing
“Takeda Strategic Collaboration and License Agreement” SEC filing
“In addition, some of our agreements, including the agreements with GlaxoSmithKline plc ("GSK"), Merck Sharp & Dohme ("Merck"), Novartis Pharma AG ("Novartis"), Nestlé Health Science ("Nestlé"), Aldevro n LLC, Roche Sequencing Solutions, Inc., Crosswalk Therapeutics and Alphazyme LLC, provide for mil...” SEC filing
“...tion, some of our agreements, including the agreements with GlaxoSmithKline plc ("GSK"), Merck Sharp & Dohme ("Merck"), Novartis Pharma AG ("Novartis"), Nestlé Health Science ("Nestlé"), Aldevro n LLC, Roche Sequencing Solutions, Inc., Crosswalk Therapeutics and Alphazyme LLC, provide for milestone...” SEC filing
“...GSK"), Merck Sharp & Dohme ("Merck"), Novartis Pharma AG ("Novartis"), Nestlé Health Science ("Nestlé"), Aldevro n LLC, Roche Sequencing Solutions, Inc., Crosswalk Therapeutics and Alphazyme LLC, provide for milestone payments, usage payments, and/or future royalty or other payments, which we will o...” SEC filing
“The Company also has the potential to receive quantity-dependent, usage payments for each API that is manufactured by Novartis using one or more enzymes that have been developed or are in development using the CodeEvolver technology platform during the period beginning on the conclusion of the Techn...” SEC filing
“We supplied the CDX‑616 enzymes under an Enzyme Supply Agreement with Pfizer Ireland Pharmaceuticals, a subsidiary of Pfizer (the "Pfizer Supply Agreement").” SEC filing
“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing
“To date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc ("GSK"), Merck & Co., Inc. ("Merck & Co") and Novartis Pharma AG ("Novartis").” SEC filing
“In December 2023, we entered into an exclusive licensing agreement with Aldevron LLC ("Aldevron"), a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron licensed our Codex HiCap RNA Polymerase.” SEC filing
Companies whose annual reports name CODEXIS, INC. 1
“Codexis, Inc. partnered with Tate & Lyle and Merck & Co., Inc. on different, highly” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.